The transactions may be subject to various regulatory approvals, exchange approvals, board approvals, shareholder approvals and other contingencies. However, the break-up fee is now binding and in place, and it further provides Heart One Global Research with separate remedies against third parties uninvolved with this transaction.
The Company shall endeavor to follow up with short market reports at least twice a week to track the status of these transactions and the developments that have occurred. The public is also requested to view Signalife's website in the upcoming days to track the development of this business combination.
Signalife, Inc. is a life sciences company focused on the monitoring, detection and prevention of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices, therapies and/or technologies that simplify and reduce the costs of cardiovascular disease.
Signalife, Inc. is traded on the American Stock Exchange under the symbol SGN. More information is located at http://www.signalife.com. Clear Data. Trusted Results.
About Heart One Global Research
Heart One Global Research is the holding company for a number of assets, including various heart management and distribution arms worldwide and also including the renowned Health One Global, Ltd. (http://www.healthoneglobal.com). The latter subsidiary is the London-based international developer and distributor of information technologies that are clinically focused, mature, stable, robust, comprehensive, flexible, portable, and standards-based electronic health record solutions.
These technologies are available in Windows, Internet and USB Drive
versions that can share a c
|SOURCE Signalife, Inc.|
Copyright©2008 PR Newswire.
All rights reserved